Drawing on extensive industry experience, Rengangyongsheng (Hong Kong) Limited (RGYS) provides end-to-end compliance services covering product classification assessments, medicine licence applications, import customs clearance and labelling reviews. We understand the complexities of cross-border pharmaceutical products under different regulatory systems and help clients develop compliance strategies to reduce approval times. Our team closely monitors the latest policies issued by the Drug Office, Department of Health, and relevant regulators to ensure that clients’ products meet current requirements, helping them enter the Hong Kong market quickly while reducing legal risks.
HONG KONG DRUG LICENSING
How does Rengangyongsheng (Hong Kong) Limited (RGYS) support clients with one-stop compliance services for cross-border pharmaceutical products?
A complete explanation of the regulatory basis, Drew Tang’s recommendations and risk alerts. The original material dates from 2025; read it alongside the latest official requirements.
Original guide, 2025 edition: These FAQs are provided for topic-based reference and have not all been individually checked against current rules. Please confirm fees, personnel, renewal, changes and product requirements against the professional in-depth guide for the relevant licence type and the official requirements in force at the time.
Back to Category J: Cross-border Medicines and Industry Practice (Q451-Q500) Search more questions